|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that over-expression of LRIG1 inhibits cell proliferation and colony formation and tumor growth, while knockdown of LRIG1 promotes cell proliferation and colony formation.
|
26159916 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that LRIG1 exerts important tumor-suppressive effects in EGFR-mutant NSCLC and has the potential to become a novel therapeutic target for EGFR-mutant NSCLC.
|
29546323 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicated that tumor volume growth was retarded via Ad-LRIG1 intratumoral injection.
|
21567105 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results are consistent with LRIG1 being a tumour suppressor gene in humans.
|
12234026 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study was conducted to investigate the possible prognostic value of molecular markers LRIG1‑2 and LIM domain 7 protein (LMO7) in vulvar squamous cell carcinoma (VSCC) and their possible correlation to human papilloma virus (HPV)‑ and p16INK4a‑status of the tumors.
|
31059071 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The positive expression rate of Fascin-1 in cancer tissue and normal tissue was 70.5% (43/61) and 13.1% (8/61), respectively, which indicated cancer tissue much higher than normal tissue (P < 0.05); for LRIG1, the positive expression rate was 54.1% (33/61) and 82.0% (50/61) for tumor tissue and normal tissue with statistical difference (P < 0.05); Fascin-1-positive expression was associated with tumor diameter (P < 0.05) and mediastinal lymph node metastasis (P < 0.05).
|
28230028 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The molecular mechanisms by which LRIG1 mediates its tumor suppressor effects and regulates receptor tyrosine kinases remain incompletely understood.
|
29317492 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of LRIG1 was decreased, while the expression of EGFR was increased in the majority of bladder cancer, and the ratio of EGFR/LRIG1 was increased in tumors versus normal tissue.
|
24314030 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor apoptosis index was found to be 8.72% in the control group and 39.7% in LRIG1-transfected mice (χ2 = 7.59, P < 0.05).
|
27173312 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Specifically, LRIG1 has been identified as a tumor suppressor in human cancers.
|
29246624 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, in the search for endogenous negative regulators of EGF receptor, LRIG1 was cloned and characterized as a putative tumor suppressor gene often downregulated in various human tumors, including astrocytic tumors.
|
23337938 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Positive LRIG1 expression was definitely related with smaller tumor size (OR: 1.64, 95% CI=1.11-2.42), early tumor stage (OR: 3.67, 95% CI=1.87-7.21), well degree of differentiation (OR: 4.35, 95% CI=2.12-8.93) and negative recurrence (OR: 0.29, 95% CI=0.16-0.53).
|
30123358 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest LRIG1 as a tumor suppressor for head and neck cancers; LRIG1 downregulation in cancer cells enhances EGFR-MAPK-SPHK1 signaling and ECM remodeling activity, leading to malignant phenotypes of head and neck cancers.
|
23624915 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
None of these genes, except LRIG1, showed expression in any of the tested tissues (including normal adult and fetal kidney, sporadic kidney tumours and tumour samples from the proband's family).
|
15016767 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, LRIG1 negatively regulates receptor tyrosine kinases and functions as a tumor suppressor.
|
30429017 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been well established that LRIG1 negatively regulates multiple growth factor signaling pathways and is considered to be a tumor suppressor; however, the biological functions of LRIG2 remain largely unexplored.
|
30015847 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased LRIG1 copy number was associated with increased levels of LRIG1 mRNA (two of three tumours) and protein (four of four tumours) in the tumours compared to matched non-neoplastic breast tissue, as assessed by RT-PCR and western blot analysis.
|
16168117 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we evaluated the mRNA expression level of LRIG1-3 in human glioma cell lines and control-matched glioma tissues, characterized the sub-cellular localization of an LRIG3-GFP fusion protein, and analyzed the relationship between sub-cellular localization of LRIG1-3 and clinical parameters in 404 astrocytic tumors by immunohistochemistry.
|
16532360 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we will discuss the ability of LRIG1 to act as a triple threat: pan-ERBB negative regulator, intestinal stem cell marker and tumour suppressor.
|
23558895 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the Swedish series, high expression of LRIG1 correlated with Gleason score, T-stage, tumor cell proliferation, vascular density and epidermal growth factor receptor (EGFR) phosphorylation.
|
21128282 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study the expression of LRIG1 (leucine rich repeats and immunoglobin-like domains 1) and its relation to EGFR (epidermal growth factor receptor) was examined in tumour samples and adjacent non-neoplastic tissues from 30 patients with colorectal cancer.
|
17851870 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In all, 31 renal cell carcinomas (RCCs) were examined for expression of the potential tumour suppressor LRIG1 (formerly Lig-1) and the epidermal growth factor receptor (EGFR).
|
14520461 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, LRIG1 knockdown promoted the tumorigenic potential in vitro, which was manifested as increased proliferation, invasiveness, and migration as well as increased tumor size in vivo in the xenograft model.
|
30248341 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, RNAi-mediated silencing of LRIG1 alters EGFRvIII intracellular trafficking and leads to enhanced EGFRvIII expression, suggesting that loss of LRIG1 in tumors may contribute to a permissive environment for EGFRvIII overexpression, contributing to EGFRvIII oncogenesis.
|
18542056 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Estrogen stimulates Lrig1 accumulation and disruption of this induction enhances estrogen-dependent tumor cell growth, suggesting that Lrig1 functions as an estrogen-regulated growth suppressor.
|
21821674 |
2011 |